Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with additional updates anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE ® in multiple solid tumor types known to express B7-H3 initiated May 2026 with updates anticipated in 2H 2026 as enrollment progresses through dose escalation cohorts Cash balance as of March 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026 SAN FRANCISCO, CALIFORNIA, May 15, 2026 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager TriKE® platform, today announced first quarter 2026 financial results for the period ended March 31, 2026. “With the initiation of our GTB-5550 Phase 1 trial, we have now advanced three TriKE® candidates into the clinic, a significant milestone that underscores the continued momentum of our pipeline,” said Michael Breen, Executive Chairman and Chief Executive Officer.
This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.
Brief Summary
GT Biopharma, Inc. (NASDAQ: GTBP) has reported its financial results for the first quarter of 2026, highlighting key developments in its ongoing clinical trials.
- $9 million cash balance as of March 31, 2026, expected to sustain operations through Q4 2026.
- Ongoing Phase 1 trial evaluating GTB-3650 TriKE® with updates to be provided in 2H 2026.
- Initiated Phase 1 basket trial for GTB-5550 TriKE® in May 2026 focused on multiple solid tumor types.
- Three TriKE® candidates are now in clinical trials, showcasing strong pipeline momentum.
Why it matters: This is a significant step for GT Biopharma as they advance their innovative immuno-oncology therapies.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.